Clinical trials: Metabolic Cardiomyopathy
Non Hodgkin Lymphoma, DLBCL
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and…
- Conditions
- Non Hodgkin Lymphoma, DLBCL, Cardiovascular Diseases, Cardiomyopathies
- Trial name
- CLARITY (NCT07041827)
- Testing
- Cardiovascular assessment
- Where
- Netherlands
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Metabolic Preparation, Myocardial Inflammation
Impact of 100mL Lipid Emulsion for Intravenous for Suppression of Myocardial Glucose Metabolism in 18F-FDG PET/CT
There is increasing evidence that [18F]-2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT is useful in the identification and treatment of disease processes that involve cardiac inflammation and infection.
- Trial name
- NCT04437927
- Where
- Monaco
- Volunteers
- 51 people
- Sponsor
- Centre Hospitalier Princesse Grace
Danon Disease
The Natural History of Danon Disease
Danon disease (DD) is a rare, X-linked disorder associated with severe cardiomyopathy, and in many cases, skeletal myopathy, and cognitive impairment caused by mutations in the LAMP2 gene.
- Trial name
- NCT03766386
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Diego
Type 2 Diabetes, Diabetic Cardiomyopathy
NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study
A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a…
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
- Trial name
- STRONG-DM (NCT06593327)
- Testing
- Intensive Prevention Strategy
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Texas Southwestern Medical Center
Beta-Thalassemia, Iron Overload
Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients
This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an…
- Trial name
- CANALI (NCT02474420)
- Testing
- Amlodipine, Deferasirox
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Kevin H.M. Kuo, MD, MSc, FRCPC
Amyloidosis
A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis
Transthyretin (TTR) is a plasma protein mainly synthesized in the liver, recognized as a transporter of thyroxine and retinol-binding protein.
- Trial name
- NCT05375279
- Testing
- Lip Salivary Gland Biopsy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Unity Health Toronto
Amyloidosis; Systemic, Amyloidosis Cardiac
Essen Amyloidosis Registry
The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis.
- Trial name
- EAR (NCT06887283)
- Where
- Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Transthyretin Amyloidosis
New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis
The development of cardiac amyloidosis is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues.
- Trial name
- NCT06345235
- Testing
- blood test
- Where
- Poland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- John Paul II Hospital, Krakow
Arrhythmogenic Cardiomyopathies
Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy
Status of the research project: The main complications of arrhythmogenic cardiomyopathies (AC) are sudden death, more rarely heart failure.
- Trial name
- CharACTPET-MR (NCT05450783)
- Testing
- Biocollection
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Nantes University Hospital
Mental Illness, Stress
HEAlth Dialogues for Patients With Mental Illness in Primary Care
In the current project, primary health care patients with mental illness such as anxiety, depression, fatigue or sleep disorders will be followed.
- Conditions
- Mental Illness, Stress, Fatigue, Sleep Disorder
- Trial name
- HEAD-MIP (NCT05181254)
- Testing
- health dialogue
- Where
- Sweden
- Volunteers
- 167 people
- Sponsor
- Region Skane
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- ASCEND-ATTR (NCT07695701)
- Testing
- Acoramidis (AG10) oral tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Diabetic Cardiomyopathies
Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With FLIM
Diabetic Cardiomyopathy (DCM) is disease of myocardial structure and function which is independent of hypertension, coronary heart disease, heart valve abnormalities, and other types of heart disease.
- Trial name
- NCT04534894
- Testing
- fluorescence lifetime imaging microscopy
- Volunteers
- 243 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Amyloidosis, Hereditary, Amyloidosis Cardiac
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein.
- Conditions
- Amyloidosis, Hereditary, Amyloidosis Cardiac, Amyloidosis, Familial, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Trial name
- NCT05489549
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Texas Southwestern Medical Center
Danon Disease
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
This is a non-randomized open-label Phase 1 study to evaluate the safety and toxicity of gene therapy using a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2…
- Trial name
- NCT03882437
- Testing
- RP-A501
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Rocket Pharmaceuticals Inc.